2 growth heroes that could make you rich

Royston Wild looks at two stocks with hot growth prospects.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

A bubbly trading statement has driven Elementis’ (LSE: ELM) share price 5% higher in Tuesday business. The chemicals maker is now dealing at its most expensive since April 2015 and is just a whisker away from punching fresh record peaks.

Elementis announced that it has enjoyed “stronger demand across most of our markets” during January-March versus the same 2016 period, with sales across its Specialty Products division (responsible for more than two-thirds of group revenues) benefitting from “notably strong growth” in its Personal Care and Energy sub-segments and a strong start from its Coatings business.

Meanwhile, Elementis’ Chromium division has also witnessed an uptick in demand outside North America, and a temporary improvement in pricing conditions is also supporting revenues at its Surfactants arm.

As a result Elementis commented that “we remain on track to grow operating profit across our three segments in 2017.”

A sage growth strategy

Elementis has not proved a stellar growth pick in recent years, the company enduring two heavy earnings dips on the bounce.

But the City expects the FTSE 250 firm to put this trouble to bed with advances of 15% and 14% in 2017 and 2018 respectively. And while Elementis subsequently deals on a forward P/E ratio of 20.6 times — peeking outside the value benchmark of 15 times — I still reckon the chemicals colossus remains an enticing pick at current prices.

Today’s release comes as welcome assurance as sales across its high-margin Personal Care and Energy arms continue to pick up the pace. And the $360m acquisition of SummitReheis in March also bolsters Elementis’ long-term growth profile, not only through bolstering its position in Personal Care but also by reducing its dependence upon the oft-unpredictable Chromium business.

The US-based company is becoming increasingly-cash generative and plans to allocate this capital to keep developing its hugely-lucrative Specialty Products operations. And I reckon this strategy should establish Elementis as a brilliant profits generator in the years ahead.

Fund star

Like Elementis, stock picker demand for Man Group (LSE: EMG) has also exploded in recent sessions, the hedge fund manager hitting one-year peaks just today.

The company’s share price has boomed 30% since the start of 2017 alone, and I believe a meaty uptick in client activity should help Man Group to keep on charging. The financial goliath recorded assets under management of $88.7bn as of March, shooting from $80.9bn just three months earlier as net inflows surged $3bn.

Man Group is also anticipated to wave goodbye to recent earnings woes and punch stratospheric growth of 45% this year and 27% in 2018. Not only do these projections leave the fund manager trading on a low forward P/E ratio of 13 times, but a PEG readout of 0.3 (below the bargain watermark of 1) underlines its exceptional value.

While Man Group is not without its share of risk thanks to a wide array of regulatory pressures, I reckon these factors are more than baked in at current prices, and that the firm offers plenty of upside at current prices as client appetite picks up.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended Elementis. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »